qa_id stringlengths 27 27 | qa_group_id stringlengths 28 32 | qa_family stringclasses 3
values | subtask_type stringclasses 7
values | qa_subtype stringclasses 3
values | cluster_id stringclasses 42
values | language stringclasses 1
value | split stringclasses 1
value | question stringlengths 148 1.41k | answer stringlengths 718 10.8k | claim_ids listlengths 0 8 | paper_ids listlengths 1 5 | evidence_span_ids listlengths 0 7 | association_ids listlengths 0 4 | hypothesis_ids listlengths 0 4 | record_json stringlengths 4.37k 33.7k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
QA:f8f992fb13d5ac6521b29f83 | QAG:29274b91ca359c84357ed031 | provenance_qa | exact_evidence_retrieval | provenance_qa | G011 | en | train | Which exact source passage supports the statement "These updates included recommendations for first-line use of checkpoint inhibitors for mCRC, that is deficient mismatch repair/microsatellite instability-high, recommendations related to the use of biosimilars, and expanded recommendations for biomarker testing"? Retur... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:50dd63555dcc74de3ab56bd7","quotes":["These updates include recommendations for first-line use of checkpoint inhib... | [
"CLM:50dd63555dcc74de3ab56bd7",
"CLM:326a05cf8a9ae0541d53b478"
] | [
"PMID:33724754"
] | [
"SPAN:0491d776163c8f0a3ef81be5",
"SPAN:87568e7214b90a4cf42271e8"
] | [] | [] | {"qa_id":"QA:f8f992fb13d5ac6521b29f83","qa_group_id":"QAG:29274b91ca359c84357ed031","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G011","question":"Which exact source passage supports the statement \"These updates included recommendations for first-line use of check... |
QA:fbbef196f0064d0415532ea3 | QAG:046b410246b6302cf0e63721 | provenance_qa | exact_evidence_retrieval | provenance_qa | G011 | en | train | Which exact source passage supports the statement "It was shown that the gut microbiota was associated with the response and toxicity of immune checkpoint inhibitor treatment"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting p... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:7587bd2d4cc157c2435f9115","quotes":["It was shown that the gut microbiota is associated with the response and tox... | [
"CLM:7587bd2d4cc157c2435f9115",
"CLM:0f2d266e21cd48e0f6a6d051"
] | [
"PMCID:PMC9818776"
] | [
"SPAN:b6507af529249a547f49ea31",
"SPAN:b7294dabc99ac6bc0ebddeba"
] | [] | [] | {"qa_id":"QA:fbbef196f0064d0415532ea3","qa_group_id":"QAG:046b410246b6302cf0e63721","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G011","question":"Which exact source passage supports the statement \"It was shown that the gut microbiota was associated with the respo... |
QA:fc50e0fcc039c3704602a08b | QAG:8edf2443ef21d238de54d18c | provenance_qa | exact_evidence_retrieval | provenance_qa | G011 | en | train | Which exact source passage supports the statement "18 The difference in treatment regimen may be attributable to the shorter survival outcomes in our trial compared with the other two trials, since the patients received irinotecan as the combination agent, whereas a fluoropyrimidine-based regimen is known to have effic... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:45bf6c996ab36d6ebb458989","quotes":["18 The difference in treatment regimen may be attributable to the shorter su... | [
"CLM:45bf6c996ab36d6ebb458989",
"CLM:0f406285c315c8e95e3cc83d"
] | [
"PMCID:PMC10334451"
] | [
"SPAN:e89f75a28d28057f16291905"
] | [] | [] | {"qa_id":"QA:fc50e0fcc039c3704602a08b","qa_group_id":"QAG:8edf2443ef21d238de54d18c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G011","question":"Which exact source passage supports the statement \"18 The difference in treatment regimen may be attributable to the ... |
QA:fe131980e48093eae172523c | QAG:82b192d3c56db740765a906c | provenance_qa | exact_evidence_retrieval | provenance_qa | G011 | en | train | Which exact source passage supports the statement "High TMB was associated with clinical response in melanoma and lung cancers, but the evidence for the usefulness of TMB in guiding the immunotherapy of gastric cancer was promising but remained inconclusive"? Return the original wording with paper, Claim, and Evidence ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:d94ca999c0faf603614c381c","quotes":["High TMB is associated with clinical response in melanoma and lung cancers, ... | [
"CLM:d94ca999c0faf603614c381c",
"CLM:01c4ee7851e149e11d672c78"
] | [
"PMCID:PMC9818776"
] | [
"SPAN:b6507af529249a547f49ea31"
] | [] | [] | {"qa_id":"QA:fe131980e48093eae172523c","qa_group_id":"QAG:82b192d3c56db740765a906c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G011","question":"Which exact source passage supports the statement \"High TMB was associated with clinical response in melanoma and lun... |
QA:01176696a4a5a5e57e391d7f | QAG:db8714abffff1ffe4627aa65 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "Abstract Background Colorectal cancer (CRC) was associated with resistance to anti-epidermal growth factor receptor (EGFR) antibodies (both acquired and intrinsic), owing to the amplification or mutation of the KRAS oncogene"? Return the original wording with paper, Cl... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:5d564ff4d49fc578fa8a689e","quotes":["Abstract Background Colorectal cancer (CRC) is associated with resistance to... | [
"CLM:5d564ff4d49fc578fa8a689e"
] | [
"PMCID:PMC7376720"
] | [
"SPAN:55bd68b0d06004e9d23d2569"
] | [] | [] | {"qa_id":"QA:01176696a4a5a5e57e391d7f","qa_group_id":"QAG:db8714abffff1ffe4627aa65","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"Abstract Background Colorectal cancer (CRC) was associated with re... |
QA:087f9b9183fdc150d1554799 | QAG:08741fa1a7ddbcab74a825e4 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "Microsatellite instability (MSI) testing was recommended in patients with curatively resected stage II CRC because deficient mismatch repair was associated with low risk of recurrence"? Return the original wording with paper, Claim, and Evidence Span references.
Integ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:b2878b7e1a982fe524bcfd19","quotes":["Microsatellite instability (MSI) testing was recommended in patients with cu... | [
"CLM:b2878b7e1a982fe524bcfd19"
] | [
"PMCID:PMC7540970"
] | [
"SPAN:64112b5ea47acf7b3790e960"
] | [] | [] | {"qa_id":"QA:087f9b9183fdc150d1554799","qa_group_id":"QAG:08741fa1a7ddbcab74a825e4","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"Microsatellite instability (MSI) testing was recommended in patien... |
QA:1241ec6936846249960b91c1 | QAG:e78204a0abee06633fa02b7a | provenance_qa | paper_evidence_availability | provenance_qa | G012 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC6439839? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC6439839","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC6439839"
] | [] | [] | [] | {"qa_id":"QA:1241ec6936846249960b91c1","qa_group_id":"QAG:e78204a0abee06633fa02b7a","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G012","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC6439839... |
QA:13e1aaf942a80775c8ea6de0 | QAG:11193938abb8e32745247efa | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "Phase II study of third-line cetuximab rechallenge in patients with metastatic wild-type K-RAS colorectal cancer who achieved a clinical benefit in response to first-line cetuximab plus chemotherapy (JACCRO-08)"? Return the original wording with paper, Claim, and Evide... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:b0cc82af750dfb6838de1398","quotes":["Phase II study\nof third-line cetuximab rechallenge in patients with metasta... | [
"CLM:b0cc82af750dfb6838de1398"
] | [
"PMID:34591420"
] | [
"SPAN:d6e9e606492ca59400f87c82"
] | [] | [] | {"qa_id":"QA:13e1aaf942a80775c8ea6de0","qa_group_id":"QAG:11193938abb8e32745247efa","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"Phase II study of third-line cetuximab rechallenge in patients wit... |
QA:150d328485973539e95b5a3c | QAG:84d05d3510f7352e6970a0cc | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "Although PUMA is required for apoptosis promoted by different stimuli in CRC cells , it may have a less critical role than Bim or other BH3-only proteins in different types of cancer cells"? Return the original wording with paper, Claim, and Evidence Span references.
... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:4fe71d6f5fa7cded438d310c","quotes":["Although PUMA is required for apoptosis induced by different stimuli in CRC ... | [
"CLM:4fe71d6f5fa7cded438d310c"
] | [
"PMCID:PMC6195818"
] | [
"SPAN:6899537a98271ee4e2329491"
] | [] | [] | {"qa_id":"QA:150d328485973539e95b5a3c","qa_group_id":"QAG:84d05d3510f7352e6970a0cc","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"Although PUMA is required for apoptosis promoted by different stim... |
QA:190c895ba0de8143aa53bb02 | QAG:8c465f501dd90cd055b6e75b | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "In contrast, our results indicate that PUMA rather than Bim functions as a key mediator of apoptosis promoted by anti-EGFR antibodies in sensitive CRC cells"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requiremen... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:cc2d6a797489e1a3ce9165da","quotes":["In contrast, our results indicate that PUMA rather than Bim functions as a k... | [
"CLM:cc2d6a797489e1a3ce9165da"
] | [
"PMCID:PMC6195818"
] | [
"SPAN:0091fc793660ec129c46eee1"
] | [] | [] | {"qa_id":"QA:190c895ba0de8143aa53bb02","qa_group_id":"QAG:8c465f501dd90cd055b6e75b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"In contrast, our results indicate that PUMA rather than Bim functi... |
QA:2217a0cbc42995c1efe3fdcf | QAG:ae5340a8e650cf2163a91f2f | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "Anti-EGFR therapies, specifically anti-EGFR monoclonal antibodies such as cetuximab and panitumumab, combined with chemotherapy have led to a survival benefit for patients with left-sided metastatic colorectal cancer (mCRC) with RAS/RAF wildtype tumors ( Heinemann et a... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:936a7df82a5838e6daa17b5c","quotes":["Anti-EGFR therapies, speci... | [
"CLM:936a7df82a5838e6daa17b5c",
"CLM:25aecad93167c3ecfa8217d6",
"CLM:9e0d2138525772805516ef3c"
] | [
"PMCID:PMC10542118",
"PMCID:PMC7865832",
"PMCID:PMC6195818"
] | [
"SPAN:c33c606ae048107493762dfb",
"SPAN:7817fa15ebdd81d6ae659277",
"SPAN:553f52f375f3b24c552a078c"
] | [
"ASC2:84b55b147d32bbab595a3973",
"ASC2:53010e58668375cdd230fb1c"
] | [
"HYP:DCH:9d7782b013ea73028e15f493",
"HYP:DCH:f580ee1346e8cff4d4d0ff8b"
] | {"qa_id":"QA:2217a0cbc42995c1efe3fdcf","qa_group_id":"QAG:ae5340a8e650cf2163a91f2f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"Anti-EGFR therapies, specifically anti-EGFR monoclonal antibodies ... |
QA:2321a8bfe18c9ed41b901558 | QAG:9e9287c1e04cfa3016d47c10 | provenance_qa | paper_evidence_availability | provenance_qa | G012 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:36200726? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable an... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMID:36200726","verdict":"no_released_traceable_claim","reason":"No Cla... | [] | [
"PMID:36200726"
] | [] | [] | [] | {"qa_id":"QA:2321a8bfe18c9ed41b901558","qa_group_id":"QAG:9e9287c1e04cfa3016d47c10","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G012","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:36200726? E... |
QA:246863529fb6293ddfdb5472 | QAG:6c5111b8800900405b952699 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "Anti-EGFR antibody therapies, including cetuximab and panitumumab, have improved the prognosis of patients with CRC, particularly in patients with the wild-type KRAS gene, in which these agents exhibit increased efficacy [ 4 – 7 ]"? Return the original wording with pap... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:c03cdb37e1e7556d32ae4eb9","quotes":["Anti-EGFR antibody therapi... | [
"CLM:c03cdb37e1e7556d32ae4eb9",
"CLM:677fc7e0c78165b169232f4a",
"CLM:46b5be9561d4f52309cd0886",
"CLM:6a2c272c5d62beb098bfadda"
] | [
"PMCID:PMC4823119",
"PMCID:PMC10803265",
"PMCID:PMC7583702"
] | [
"SPAN:ce27b1160ab5e48cff9b93a5",
"SPAN:e9fcda7b9b8748b3e2289d20",
"SPAN:a73f0eb9cb958986b113eb07",
"SPAN:e5ec78c35b3ad26ffeb87e44"
] | [
"ASC2:7c9c0c303f08c70dc9fd6702",
"ASC2:e543d232f7c65f1fae4564d6"
] | [
"HYP:DCH:5afabd029752ebc3c065b5e1",
"HYP:DCH:7c0c867b06c9e46352e9cef4"
] | {"qa_id":"QA:246863529fb6293ddfdb5472","qa_group_id":"QAG:6c5111b8800900405b952699","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"Anti-EGFR antibody therapies, including cetuximab and panitumumab,... |
QA:252eec07dfe9279acdb94f2b | QAG:b97695102a93bc2aa3e4ca08 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "Patients were included in our analysis if they met the following criteria: histologically confirmed RAS and BRAF wild-type colorectal cancer, first-line anti-EGFR-based therapy with documentation of progression to first-line therapy within 4 weeks after the last admini... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:d9898dfcc151b288bf13cd9a","quotes":["Patients were included in our analysis if they met ... | [
"CLM:d9898dfcc151b288bf13cd9a",
"CLM:e411b1b75ece3ac911617438",
"CLM:c2b7ecbc68ee132710b32beb"
] | [
"PMCID:PMC9068964",
"PMCID:PMC7529530",
"PMCID:PMC6822250"
] | [
"SPAN:eaf521be704ef354dea33052",
"SPAN:1eb3dacd649a5a4c446d0110",
"SPAN:736807e56d84a0af3faa6263"
] | [
"ASC2:2bd397b73c46f8805a5e83dd",
"ASC2:fad50595b6a6dd0be93c90aa"
] | [
"HYP:DCH:e203b2223c35582ef72d444d"
] | {"qa_id":"QA:252eec07dfe9279acdb94f2b","qa_group_id":"QAG:b97695102a93bc2aa3e4ca08","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"Patients were included in our analysis if they met the following c... |
QA:27dbcdd1d43a261710266076 | QAG:8e0b35b254401f18beff2420 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "These observations, along with ours, suggest that CRC cells with KRAS alterations are addicted to hyperactive mitotic kinases, which lead to increased cell cycle progression and cell proliferation in cells with increased KRAS activity"? Return the original wording with... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:368190edd4739bb14a89a30f","quotes":["These observations, along with ours, suggest that CRC cells with KRAS altera... | [
"CLM:368190edd4739bb14a89a30f"
] | [
"PMCID:PMC6195818"
] | [
"SPAN:a7de2d222f855b07648ad34f"
] | [] | [] | {"qa_id":"QA:27dbcdd1d43a261710266076","qa_group_id":"QAG:8e0b35b254401f18beff2420","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"These observations, along with ours, suggest that CRC cells with K... |
QA:2b05ab2108fb8824df212ac9 | QAG:96339ef93dde77104fedd2b9 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "Taken together, KRAS mutations in CRC cells inhibited the activation of AMPK pathway in response to anti-EGFR antibody treatment"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact support... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:2a612317a59d104e41af062c","quotes":["Taken together, KRAS mutations in CRC cells suppressed the activation of AMP... | [
"CLM:2a612317a59d104e41af062c"
] | [
"PMCID:PMC7376720"
] | [
"SPAN:9dbc75a77167c222fbe8aef5"
] | [] | [] | {"qa_id":"QA:2b05ab2108fb8824df212ac9","qa_group_id":"QAG:96339ef93dde77104fedd2b9","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"Taken together, KRAS mutations in CRC cells inhibited the activati... |
QA:2e086f26efdfd30d8a031cf7 | QAG:460086a23198622094dce321 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "Treating DiFi and CCK-81 CRC cells with cetuximab or panitumumab inhibited cell growth in a dose-dependent manner ( Fig. 1A and S1A )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact su... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9e0d2138525772805516ef3c","quotes":["Treating DiFi and CCK-81 C... | [
"CLM:9e0d2138525772805516ef3c",
"CLM:936a7df82a5838e6daa17b5c",
"CLM:25aecad93167c3ecfa8217d6",
"CLM:f919c5d13335b1660a98a88c"
] | [
"PMCID:PMC6195818",
"PMCID:PMC10542118",
"PMCID:PMC7865832",
"PMCID:PMC9161494"
] | [
"SPAN:553f52f375f3b24c552a078c",
"SPAN:7817fa15ebdd81d6ae659277",
"SPAN:c33c606ae048107493762dfb",
"SPAN:797bc99e27febbbc112b7928"
] | [
"ASC2:84b55b147d32bbab595a3973",
"ASC2:53010e58668375cdd230fb1c",
"ASC2:7e8e4dfcbd4dbaa8fca33dc2"
] | [
"HYP:DCH:37b0cb4301434544bb5cf592"
] | {"qa_id":"QA:2e086f26efdfd30d8a031cf7","qa_group_id":"QAG:460086a23198622094dce321","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"Treating DiFi and CCK-81 CRC cells with cetuximab or panitumumab i... |
QA:30751ec42541525f94f89cb5 | QAG:7f114db90348806c3a591f28 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "levels 1, 2, and R1) was utilized to ensure that genes relevant for the management of approved therapies in colorectal cancer were included which identified BRAF , ERBB2 , KRAS , NRAS , and MSI-H. We then expanded this to 33 genes in total to encompass relevant genes a... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:2c2ad7b4793e9ebf3eaa2b91","quotes":["30 ; levels 1, 2, and R1) was utilized to ensure that genes relevant for the... | [
"CLM:2c2ad7b4793e9ebf3eaa2b91"
] | [
"PMCID:PMC9975664"
] | [
"SPAN:73046fb3b052588597ae6b99"
] | [] | [] | {"qa_id":"QA:30751ec42541525f94f89cb5","qa_group_id":"QAG:7f114db90348806c3a591f28","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"levels 1, 2, and R1) was utilized to ensure that genes relevant fo... |
QA:3356947538c2ebd0f052ccc4 | QAG:4bc0ce00fdea7b78a3869657 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "In this prospective multicenter cohort study, 103 patients diagnosed with stage I-IV CRC were enrolled at the University Medical Center, Thu Duc city Hospital, and Medical Genetics Institute in Ho Chi Minh city, Vietnam from April 2021 to June 2022. Patients must be at... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:95d943138ff7a45e57061fdb","quotes":["In this prospective multicenter cohort study, 103 patients diagnosed with st... | [
"CLM:95d943138ff7a45e57061fdb"
] | [
"PMCID:PMC9792166"
] | [
"SPAN:7c2c478b76853cb648dc12fe"
] | [] | [] | {"qa_id":"QA:3356947538c2ebd0f052ccc4","qa_group_id":"QAG:4bc0ce00fdea7b78a3869657","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"In this prospective multicenter cohort study, 103 patients diagnos... |
QA:3496d24c6be65a6d2002ca54 | QAG:551d27925ca5a0acb1329564 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "Advances in systemic chemotherapies have led to significant improvements in survival for patients with metastatic CRC"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:4376b243d1cef94681a2dc33","quotes":["Advances in systemic chemotherapies have led to significant improvements in ... | [
"CLM:4376b243d1cef94681a2dc33"
] | [
"PMCID:PMC4823119"
] | [
"SPAN:1e0b4a509192ae5899b31434"
] | [] | [] | {"qa_id":"QA:3496d24c6be65a6d2002ca54","qa_group_id":"QAG:551d27925ca5a0acb1329564","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"Advances in systemic chemotherapies have led to significant improv... |
QA:3557941a45eb47f68c35e887 | QAG:749169b1a857c0e80dfaea44 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "4 In CRC cell lines and patients treated with cetuximab, development of the S492R mutation in the EGFR cetuximab-binding epitope conferred resistance to cetuximab therapy"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provena... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:6a2c272c5d62beb098bfadda","quotes":["4 In CRC cell lines and pa... | [
"CLM:6a2c272c5d62beb098bfadda",
"CLM:46b5be9561d4f52309cd0886",
"CLM:071c88dbfad236ead4146298"
] | [
"PMCID:PMC7583702",
"PMCID:PMC10803265",
"PMCID:PMC7865832"
] | [
"SPAN:e5ec78c35b3ad26ffeb87e44",
"SPAN:a73f0eb9cb958986b113eb07",
"SPAN:e42229b2d6d83199da1108a2"
] | [
"ASC2:e543d232f7c65f1fae4564d6",
"ASC2:e14b16f215fc304e5e344990"
] | [
"HYP:DCH:275a26f4e420c3f2a81b06c2",
"HYP:DCH:43915a13dad47c9daf3e602f"
] | {"qa_id":"QA:3557941a45eb47f68c35e887","qa_group_id":"QAG:749169b1a857c0e80dfaea44","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"4 In CRC cell lines and patients treated with cetuximab, developme... |
QA:4afd1c5f96ae595c66bcc6c7 | QAG:2c6430e59d945a7b03c4db03 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "This is achieved through enabling the administration of anti-EGFR that was initially rejected on the basis of previous molecular testing of tissue"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:628071f041a8c868a28ad76b","quotes":["This is achieved through enabling the administration of anti-EGFR that was i... | [
"CLM:628071f041a8c868a28ad76b"
] | [
"PMCID:PMC7529530"
] | [
"SPAN:edf4d5911177960d7436f1ba",
"SPAN:f23e18756ef06dec0baf464f"
] | [] | [] | {"qa_id":"QA:4afd1c5f96ae595c66bcc6c7","qa_group_id":"QAG:2c6430e59d945a7b03c4db03","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"This is achieved through enabling the administration of anti-EGFR ... |
QA:4f2db332550ea4caa0f83bd1 | QAG:c8ef554edb034fbcf0d54796 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "Thus, the activation of AMPK inhibited the mTOR pathway and eventually reduced the translation of Mcl-1 in CRC"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with p... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:8aacb45214344d7074179e2a","quotes":["Thus, the activation of AMPK suppressed the mTOR pathway and eventually redu... | [
"CLM:8aacb45214344d7074179e2a"
] | [
"PMCID:PMC7376720"
] | [
"SPAN:b8f8481281d63164ac449ebe"
] | [] | [] | {"qa_id":"QA:4f2db332550ea4caa0f83bd1","qa_group_id":"QAG:c8ef554edb034fbcf0d54796","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"Thus, the activation of AMPK inhibited the mTOR pathway and eventu... |
QA:55629f2204b9fa1925e31173 | QAG:f71c746a230cb3c3969e5171 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "Although the use of cetuximab has greatly improved the clinical outcomes of metastatic CRC, the discovery of resistance to anti-EGFR monoclonal antibodies promoted interest in the study of drug resistance, including abnormal molecules in the EGFR pathway, abnormal acti... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:5bb636cf2619b444f4e5fade","quotes":["Although the use of cetuximab has greatly improved the clinical outcomes of ... | [
"CLM:5bb636cf2619b444f4e5fade"
] | [
"PMCID:PMC7865832"
] | [
"SPAN:e42229b2d6d83199da1108a2"
] | [] | [] | {"qa_id":"QA:55629f2204b9fa1925e31173","qa_group_id":"QAG:f71c746a230cb3c3969e5171","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"Although the use of cetuximab has greatly improved the clinical ou... |
QA:57fa42e6657d7f6ddd357629 | QAG:34c70eed6009e2d24bf4c62a | provenance_qa | paper_evidence_availability | provenance_qa | G012 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC10196928? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiabl... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC10196928","verdict":"no_released_traceable_claim","reason":"No... | [] | [
"PMCID:PMC10196928"
] | [] | [] | [] | {"qa_id":"QA:57fa42e6657d7f6ddd357629","qa_group_id":"QAG:34c70eed6009e2d24bf4c62a","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G012","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC1019692... |
QA:5a06204b84086a1f169ed729 | QAG:4793b8b4b82a8572d6af6c99 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "No NRAS mutant cases were enrolled as the licensed cetuximab (CET) indication changed to KRAS and NRAS WT CRC during the trial"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supportin... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:6ccc3880d4186685e452727a","quotes":["No NRAS mutant cases were enrolled as the licensed ... | [
"CLM:6ccc3880d4186685e452727a",
"CLM:677fc7e0c78165b169232f4a"
] | [
"PMCID:PMC6617392",
"PMCID:PMC10803265"
] | [
"SPAN:aaddcb23a35f3cd789acc408",
"SPAN:e9fcda7b9b8748b3e2289d20"
] | [
"ASC2:a3f318a0b785427cdaa2d038"
] | [] | {"qa_id":"QA:5a06204b84086a1f169ed729","qa_group_id":"QAG:4793b8b4b82a8572d6af6c99","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"No NRAS mutant cases were enrolled as the licensed cetuximab (CET)... |
QA:5c7b8d19209d9bcbd068c69c | QAG:0322a5505e7a7e4553087d09 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "Anti-EGFR antibody therapies, including cetuximab and panitumumab, have improved the prognosis of patients with CRC, particularly in patients with the wild-type KRAS gene, in which these agents exhibit enhanced efficacy [ 4 – 7 ]"? Return the original wording with pape... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:d2cf903a5bc106c0b3dce6ca","quotes":["Anti-EGFR antibody therapies, including cetuximab and panitumumab, have impr... | [
"CLM:d2cf903a5bc106c0b3dce6ca"
] | [
"PMCID:PMC4823119"
] | [
"SPAN:ce27b1160ab5e48cff9b93a5"
] | [] | [] | {"qa_id":"QA:5c7b8d19209d9bcbd068c69c","qa_group_id":"QAG:0322a5505e7a7e4553087d09","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"Anti-EGFR antibody therapies, including cetuximab and panitumumab,... |
QA:5da51b8a3c0d46412bd1f8af | QAG:863aaa4e1685cd70827ee32f | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "Thus, the activation of AMPK suppressed the mTOR pathway and eventually decreased the translation of Mcl-1 in CRC"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage wit... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:06a60d5d35a3fb60a124d685","quotes":["Thus, the activation of AMPK suppressed the mTOR pathway and eventually redu... | [
"CLM:06a60d5d35a3fb60a124d685"
] | [
"PMCID:PMC7376720"
] | [
"SPAN:b8f8481281d63164ac449ebe"
] | [] | [] | {"qa_id":"QA:5da51b8a3c0d46412bd1f8af","qa_group_id":"QAG:863aaa4e1685cd70827ee32f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"Thus, the activation of AMPK suppressed the mTOR pathway and event... |
QA:5da8c7c9638cb6e22b0f4307 | QAG:fb75d60adb96922c4a137668 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "The clinical outcome of patients with metastatic CRC (mCRC) has been improved by the introduction of cetuximab and panitumumab, two monoclonal antibodies targeting the epidermal growth factor receptor (EGFR)"? Return the original wording with paper, Claim, and Evidence... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:25aecad93167c3ecfa8217d6","quotes":["The clinical outcome of patients with metastatic CR... | [
"CLM:25aecad93167c3ecfa8217d6",
"CLM:f919c5d13335b1660a98a88c"
] | [
"PMCID:PMC7865832",
"PMCID:PMC9161494"
] | [
"SPAN:7817fa15ebdd81d6ae659277",
"SPAN:797bc99e27febbbc112b7928"
] | [
"ASC2:d882c788f5cbbb35c24c3a4a"
] | [] | {"qa_id":"QA:5da8c7c9638cb6e22b0f4307","qa_group_id":"QAG:fb75d60adb96922c4a137668","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"The clinical outcome of patients with metastatic CRC (mCRC) has be... |
QA:5e404ef442019de7dfeb9949 | QAG:6f82e328c2620ed9f95f17da | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "Therefore, this prospective multicenter study followed 34 patients with metastatic colorectal cancer who were tissue‐tested as RAS wild‐type (exons 2–4) during routine work‐up and received third‐line cetuximab monotherapy"? Return the original wording with paper, Claim... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:c2b7ecbc68ee132710b32beb","quotes":["Therefore, this prospective multicenter study follo... | [
"CLM:c2b7ecbc68ee132710b32beb",
"CLM:d9898dfcc151b288bf13cd9a"
] | [
"PMCID:PMC6822250",
"PMCID:PMC9068964"
] | [
"SPAN:736807e56d84a0af3faa6263",
"SPAN:eaf521be704ef354dea33052"
] | [
"ASC2:fad50595b6a6dd0be93c90aa"
] | [
"HYP:DCH:f60b7eefd3eb522f52f7bee9"
] | {"qa_id":"QA:5e404ef442019de7dfeb9949","qa_group_id":"QAG:6f82e328c2620ed9f95f17da","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"Therefore, this prospective multicenter study followed 34 patients... |
QA:6056f3f6957e0d18be683b20 | QAG:8a248b9ff7a905d714b37d9b | provenance_qa | paper_evidence_availability | provenance_qa | G012 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC10093522? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiabl... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC10093522","verdict":"no_released_traceable_claim","reason":"No... | [] | [
"PMCID:PMC10093522"
] | [] | [] | [] | {"qa_id":"QA:6056f3f6957e0d18be683b20","qa_group_id":"QAG:8a248b9ff7a905d714b37d9b","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G012","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC1009352... |
QA:67d3dd7fd33e6484e818a301 | QAG:25de4ebbd0ff369da0df4456 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "Here, we demonstrate that KRAS mutation in CRC inhibited the activation of AMPK to stimulate the translation of myeloid cell leukemia 1 (Mcl-1) via the activation of the mammalian target of rapamycin (mTOR) pathway"? Return the original wording with paper, Claim, and E... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:1991571e915a1ac6247e9118","quotes":["Here, we demonstrate that KRAS mutation in CRC suppressed the activation of ... | [
"CLM:1991571e915a1ac6247e9118"
] | [
"PMCID:PMC7376720"
] | [
"SPAN:99aaf75330027ee717e5082e"
] | [] | [] | {"qa_id":"QA:67d3dd7fd33e6484e818a301","qa_group_id":"QAG:25de4ebbd0ff369da0df4456","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"Here, we demonstrate that KRAS mutation in CRC inhibited the activ... |
QA:6b550d2e03933bb646e10a47 | QAG:1b40b8b0e457d8d2ae100066 | provenance_qa | paper_evidence_availability | provenance_qa | G012 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC10249423? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiabl... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC10249423","verdict":"no_released_traceable_claim","reason":"No... | [] | [
"PMCID:PMC10249423"
] | [] | [] | [] | {"qa_id":"QA:6b550d2e03933bb646e10a47","qa_group_id":"QAG:1b40b8b0e457d8d2ae100066","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G012","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC1024942... |
QA:71a4cd1cc6c77492fd26155c | QAG:cd2af472bebd457a62cdddfc | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "Thus, KRAS mutation in CRC cells inhibited the activation of AMPK via glycolysis"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and Evidence Span... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:dbb68d140a96660b7da71d76","quotes":["Thus, KRAS mutation in CRC cells suppressed the activation of AMPK via glyco... | [
"CLM:dbb68d140a96660b7da71d76"
] | [
"PMCID:PMC7376720"
] | [
"SPAN:1d8398896766d612622d06ca"
] | [] | [] | {"qa_id":"QA:71a4cd1cc6c77492fd26155c","qa_group_id":"QAG:cd2af472bebd457a62cdddfc","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"Thus, KRAS mutation in CRC cells inhibited the activation of AMPK ... |
QA:7396932946a290762b6c010f | QAG:e2e1228af12f49e04f210aa2 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "Inhibition of aurora kinases preferentially kills mutant KRAS CRC cells and overcomes KRAS conferred resistance to anti-EGFR antibodies in vitro and in vivo by restoring PUMA induction"? Return the original wording with paper, Claim, and Evidence Span references.
Inte... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:950771a6a5c45179186227f3","quotes":["Inhibition of aurora kinases preferentially kills m... | [
"CLM:950771a6a5c45179186227f3",
"CLM:24524626a96ad1aa62b7fb38",
"CLM:fb9e7247c525e455f4daa953",
"CLM:d262e732ecd85e6bf7331a61"
] | [
"PMCID:PMC6195818",
"PMCID:PMC7376720",
"PMCID:PMC7540970"
] | [
"SPAN:99dd1e6e2d263653881f3ddb",
"SPAN:15e88f45ffc35dcf5e82a1a5",
"SPAN:cf9277256f268b215e2f2aa1",
"SPAN:9d52784a8a0138ae01f537a4"
] | [
"ASC2:e0b9c59f68d7dae71649a6f3",
"ASC2:e73c4c1a7a3cf2382327d340"
] | [
"HYP:DCH:1753e832ff92d8f2e6755bbe"
] | {"qa_id":"QA:7396932946a290762b6c010f","qa_group_id":"QAG:e2e1228af12f49e04f210aa2","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"Inhibition of aurora kinases preferentially kills mutant KRAS CRC ... |
QA:752e1d62d54095f5ff354568 | QAG:dd97b1290d7c6e07a61514b2 | provenance_qa | paper_evidence_availability | provenance_qa | G012 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC10581628? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiabl... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC10581628","verdict":"no_released_traceable_claim","reason":"No... | [] | [
"PMCID:PMC10581628"
] | [] | [] | [] | {"qa_id":"QA:752e1d62d54095f5ff354568","qa_group_id":"QAG:dd97b1290d7c6e07a61514b2","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G012","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC1058162... |
QA:7925b47542c1a41af8f4477a | QAG:884cf597c67d9368cf182a95 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "b DLD1 WT (+/−) transfected with control or AMPK shRNA received 5 nM Cet for 48 h"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and Evidence Spa... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:c58c6eb2aeff313eca8cff28","quotes":["Fig. 4 Kras mutation in CRC suppressed AMPK activation to stabilize Mcl-1. a... | [
"CLM:c58c6eb2aeff313eca8cff28"
] | [
"PMCID:PMC7376720"
] | [
"SPAN:d989c0fed6a0d705df166515"
] | [] | [] | {"qa_id":"QA:7925b47542c1a41af8f4477a","qa_group_id":"QAG:884cf597c67d9368cf182a95","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"b DLD1 WT (+/−) transfected with control or AMPK shRNA received 5 ... |
QA:79e5ab7ef9fbbeb3e898de19 | QAG:407562ddf8065ea3b1d337d6 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "However, retrospective analyses and phase II single-arm trials showed promising activity of re-using anti-EGFRs in metastatic colorectal cancer (mCRC) patients who previously achieved benefit from a first-line anti-EGFR-based treatment"? Return the original wording wit... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:46c272df37b92f08e0d6d1c8","quotes":["However, retrospective analyses and phase II single-arm trials showed promis... | [
"CLM:46c272df37b92f08e0d6d1c8"
] | [
"PMID:34364814"
] | [
"SPAN:349a4944ee748392f469c1ef"
] | [] | [] | {"qa_id":"QA:79e5ab7ef9fbbeb3e898de19","qa_group_id":"QAG:407562ddf8065ea3b1d337d6","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"However, retrospective analyses and phase II single-arm trials sho... |
QA:7ef35df346e4218270dad5b5 | QAG:43ce109cf115880f211fecfe | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "Plasma samples were obtained from 18 patients with histologically confirmed metastatic CRC who received cetuximab-based therapy at Kinki University Hospital between November 2008 and October 2011. RESIST version 1.1 was used to assess best overall response"? Return the... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:39adfc2ef98d8d988c45d28e","quotes":["Plasma samples were obtained from 18 patients with histologically confirmed ... | [
"CLM:39adfc2ef98d8d988c45d28e"
] | [
"PMCID:PMC4823119"
] | [
"SPAN:ed6697c98c550be6dc7b319a"
] | [] | [] | {"qa_id":"QA:7ef35df346e4218270dad5b5","qa_group_id":"QAG:43ce109cf115880f211fecfe","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"Plasma samples were obtained from 18 patients with histologically ... |
QA:7f01cf0df222a5622995e35d | QAG:ec3b958479b837268fc69ea1 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "In two phase III trials comparing FOLFOX with or without cetuximab as adjuvant therapy for curatively resected stage III colon cancer, the addition of cetuximab did not improve the recurrence‐free survival (RFS) or OS, even in patients with wild‐type KRAS exon 2. 5 , 6... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:fb9e7247c525e455f4daa953","quotes":["In two phase III trials comparing FOLFOX with or wi... | [
"CLM:fb9e7247c525e455f4daa953",
"CLM:c03cdb37e1e7556d32ae4eb9"
] | [
"PMCID:PMC7540970",
"PMCID:PMC4823119"
] | [
"SPAN:cf9277256f268b215e2f2aa1",
"SPAN:ce27b1160ab5e48cff9b93a5"
] | [
"ASC2:4c73acec7df35dfe032fc331"
] | [
"HYP:DCH:92105fc7ae7786feb686ca72"
] | {"qa_id":"QA:7f01cf0df222a5622995e35d","qa_group_id":"QAG:ec3b958479b837268fc69ea1","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"In two phase III trials comparing FOLFOX with or without cetuximab... |
QA:854f3def31325aeaeebd4778 | QAG:165b3e51e09157ffb1b8ca95 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "Specifically, HER2 amplification was shown to evolve in non-small cell lung cancer (NSCLC) and CRC cell lines after prolonged exposure to cetuximab"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: retur... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:f5748d58c0e5ce83e1ad3882","quotes":["Specifically, HER2 amplification was shown to evolve in non-small cell lung ... | [
"CLM:f5748d58c0e5ce83e1ad3882"
] | [
"PMCID:PMC4823119"
] | [
"SPAN:6537c9f6cd7222b43713dbf0"
] | [] | [] | {"qa_id":"QA:854f3def31325aeaeebd4778","qa_group_id":"QAG:165b3e51e09157ffb1b8ca95","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"Specifically, HER2 amplification was shown to evolve in non-small ... |
QA:875a168d491aaba6f5bd09a8 | QAG:f9597dcbeaa27bdd755286a0 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "In the last years, the use of standard chemotherapy and targeted agents has considerably increased the prognosis of metastatic colorectal cancer (mCRC) patients, with an improvement in median overall survival (OS) to approximately 36 months ( 2 )"? Return the original ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ba36f07c4e03bd352fb3571d","quotes":["In the last years, the use of standard chemotherapy and targeted agents has ... | [
"CLM:ba36f07c4e03bd352fb3571d"
] | [
"PMCID:PMC9969187"
] | [
"SPAN:a5873dcb6a055ce9eb9fd6a0"
] | [] | [] | {"qa_id":"QA:875a168d491aaba6f5bd09a8","qa_group_id":"QAG:f9597dcbeaa27bdd755286a0","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"In the last years, the use of standard chemotherapy and targeted a... |
QA:8cd2b9627bce652f8661bd83 | QAG:4f2b197cfc2f3877a422af18 | provenance_qa | paper_evidence_availability | provenance_qa | G012 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC8531995? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC8531995","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC8531995"
] | [] | [] | [] | {"qa_id":"QA:8cd2b9627bce652f8661bd83","qa_group_id":"QAG:4f2b197cfc2f3877a422af18","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G012","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC8531995... |
QA:966ec258396af716c271dfcb | QAG:69031f8dc95e2b629e192d78 | provenance_qa | paper_evidence_availability | provenance_qa | G012 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:32961317? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable an... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMID:32961317","verdict":"no_released_traceable_claim","reason":"No Cla... | [] | [
"PMID:32961317"
] | [] | [] | [] | {"qa_id":"QA:966ec258396af716c271dfcb","qa_group_id":"QAG:69031f8dc95e2b629e192d78","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G012","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:32961317? E... |
QA:981da914a4df509caebb22f2 | QAG:9204e2857013f73a3eee5729 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "HER2 positivity predicted unresponsiveness to EGFR-targeted treatment in metastatic colorectal cancer"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Cla... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:b787164cb21b70aa1ae53cc3","quotes":["29. Sartore-Bianchi A, et al. HER2 positivity predicts unresponsiveness to E... | [
"CLM:b787164cb21b70aa1ae53cc3"
] | [
"PMCID:PMC9386661"
] | [
"SPAN:f02a01cc266e4363c6ed6bff"
] | [] | [] | {"qa_id":"QA:981da914a4df509caebb22f2","qa_group_id":"QAG:9204e2857013f73a3eee5729","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"HER2 positivity predicted unresponsiveness to EGFR-targeted treatm... |
QA:98b25f2e3adde33060cb56ad | QAG:cd72402534c31e1fa4d0a17e | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "4 Kras mutation in CRC inhibited AMPK activation to stabilize Mcl-1. a Western blot of indicated proteins in DLD1 WT (+/−) and Kras mutation (G13D/−) cells treated with 5 nM Cet for indicated time points. b DLD1 WT (+/−) transfected with control or AMPK shRNA were trea... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:fdaecd31bb6fe22bece23a22","quotes":["Fig. 4 Kras mutation in CRC suppressed AMPK activation to stabilize Mcl-1. a... | [
"CLM:fdaecd31bb6fe22bece23a22"
] | [
"PMCID:PMC7376720"
] | [
"SPAN:d989c0fed6a0d705df166515"
] | [] | [] | {"qa_id":"QA:98b25f2e3adde33060cb56ad","qa_group_id":"QAG:cd72402534c31e1fa4d0a17e","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"4 Kras mutation in CRC inhibited AMPK activation to stabilize Mcl-... |
QA:98cd86d90abffc53381b8a0e | QAG:5302f2016e3768142be92af1 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "Consistent with the results of previous studies, we found that KRAS mutation inhibited the activation of AMPK and imparted resistance to anti-EGFR antibody treatment in CRC"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated prove... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:123f87e41f3f583a5a2a3dbe","quotes":["Consistent with the results of previous studies, we found that KRAS mutation... | [
"CLM:123f87e41f3f583a5a2a3dbe"
] | [
"PMCID:PMC7376720"
] | [
"SPAN:7dba0703e58695a3983eb9b2"
] | [] | [] | {"qa_id":"QA:98cd86d90abffc53381b8a0e","qa_group_id":"QAG:5302f2016e3768142be92af1","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"Consistent with the results of previous studies, we found that KRA... |
QA:9f7957886c41e06c0c62f7ea | QAG:144ffddf3a5f75b13f55020e | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "Abstract Introduction Activating RAS gene mutations occur in approximately 55% of patients with metastatic colorectal cancer (mCRC) and was associated with poorer clinical outcomes due to epidermal growth factor receptor (EGFR) blockade resistance"? Return the original... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:4af2516daa1c4e0181387bd0","quotes":["Abstract Introduction Activating RAS gene mutations... | [
"CLM:4af2516daa1c4e0181387bd0",
"CLM:7b1ef978469d78e11aeb7906"
] | [
"PMCID:PMC10712701",
"PMCID:PMC7540970"
] | [
"SPAN:92490d5da3e03b8cc7203112",
"SPAN:15c4eb45d50ca99310a72f41"
] | [
"ASC2:63a1788e84bb30371d13155e"
] | [
"HYP:DCH:52eb73fafeb278d1e648f473"
] | {"qa_id":"QA:9f7957886c41e06c0c62f7ea","qa_group_id":"QAG:144ffddf3a5f75b13f55020e","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"Abstract Introduction Activating RAS gene mutations occur in appro... |
QA:a121862d9f2dea5a66b11981 | QAG:c678a7422ed36c6122614df6 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "Furthermore, Siena et al reported that trastuzumab and lapatinib combination therapy promoted a partial response in seven of 22 patients (32%) with HER2-positive CRC who were resistant to anti-EGFR antibody therapy"? Return the original wording with paper, Claim, and E... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:d152fdd036ce027bfe204815","quotes":["Furthermore, Siena et al reported that trastuzumab and lapatinib combination... | [
"CLM:d152fdd036ce027bfe204815"
] | [
"PMCID:PMC4823119"
] | [
"SPAN:9d67bb6d1060b93a162ae597"
] | [] | [] | {"qa_id":"QA:a121862d9f2dea5a66b11981","qa_group_id":"QAG:c678a7422ed36c6122614df6","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"Furthermore, Siena et al reported that trastuzumab and lapatinib c... |
QA:a254f3315cfd7c2bb74e84ea | QAG:3f9139b9c5c6dd275ed98281 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "We investigated the function of AMPK in KRAS mutation promoted resistance to anti-EGFR antibodies in CRC cells"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with p... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:38ced18e2610af60ca92eb31","quotes":["We investigated the function of AMPK in KRAS mutation-induced resistance to ... | [
"CLM:38ced18e2610af60ca92eb31"
] | [
"PMCID:PMC7376720"
] | [
"SPAN:03b3e9e150393a9ee4fb113b"
] | [] | [] | {"qa_id":"QA:a254f3315cfd7c2bb74e84ea","qa_group_id":"QAG:3f9139b9c5c6dd275ed98281","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"We investigated the function of AMPK in KRAS mutation promoted res... |
QA:ad7e3b53b477e7106ad058ad | QAG:58a81903d68d1e0e65d16dbd | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "While the addition of anti–EGFR antibody improved the overall survival (OS) and progression‐free survival (PFS) in patients with RAS wild‐type left‐sided colon cancer, anti–EGFR antibody therapy was not beneficial in those with right‐sided colon cancer"? Return the ori... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:7b1ef978469d78e11aeb7906","quotes":["While the addition of anti–EGFR antibody significantly improved the overall ... | [
"CLM:7b1ef978469d78e11aeb7906"
] | [
"PMCID:PMC7540970"
] | [
"SPAN:15c4eb45d50ca99310a72f41"
] | [] | [] | {"qa_id":"QA:ad7e3b53b477e7106ad058ad","qa_group_id":"QAG:58a81903d68d1e0e65d16dbd","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"While the addition of anti–EGFR antibody improved the overall surv... |
QA:ae4918b33423477b466dce9d | QAG:6b9269aed2ce288c3861a4d8 | provenance_qa | paper_evidence_availability | provenance_qa | G012 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC8176979? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC8176979","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC8176979"
] | [] | [] | [] | {"qa_id":"QA:ae4918b33423477b466dce9d","qa_group_id":"QAG:6b9269aed2ce288c3861a4d8","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G012","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC8176979... |
QA:afac9680e01834dd6f6d0417 | QAG:b7292e5e5a288e3bd2a5571f | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "Molinari F, Felicioni L, Buscarino M, De Dosso S, Buttitta F, Malatesta S, Movilia A, Luoni M, Boldorini R, Alabiso O et al (2011) increased detection sensitivity for KRAS mutations enhances the prediction of anti‐EGFR monoclonal antibody resistance in metastatic color... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:fedd6296a547502195874946","quotes":["Nature 486, 532–536. Molinari F, Felicioni L, Buscarino M, De Dosso S, Butti... | [
"CLM:fedd6296a547502195874946"
] | [
"PMCID:PMC6822250"
] | [
"SPAN:70a2050d3f193bb35e49d986"
] | [] | [] | {"qa_id":"QA:afac9680e01834dd6f6d0417","qa_group_id":"QAG:b7292e5e5a288e3bd2a5571f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"Molinari F, Felicioni L, Buscarino M, De Dosso S, Buttitta F, Mala... |
QA:b110ae16b8d2ec2fe299746c | QAG:0829863a30bbb3c84276cf0b | provenance_qa | paper_evidence_availability | provenance_qa | G012 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC10166888? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiabl... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC10166888","verdict":"no_released_traceable_claim","reason":"No... | [] | [
"PMCID:PMC10166888"
] | [] | [] | [] | {"qa_id":"QA:b110ae16b8d2ec2fe299746c","qa_group_id":"QAG:0829863a30bbb3c84276cf0b","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G012","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC1016688... |
QA:bc628e5589275219bc882f0f | QAG:a3e2352962106076ea36967b | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "Patients must be at least 18 years old, eligible for curative-intent surgery and had not received any cancer treatment, or experienced recurrence prior to the time of study entry"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9155ed3e7b7163bd18122ed7","quotes":["In this prospective multicenter cohort study, 103 patients diagnosed with st... | [
"CLM:9155ed3e7b7163bd18122ed7"
] | [
"PMCID:PMC9792166"
] | [
"SPAN:7c2c478b76853cb648dc12fe"
] | [] | [] | {"qa_id":"QA:bc628e5589275219bc882f0f","qa_group_id":"QAG:a3e2352962106076ea36967b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"Patients must be at least 18 years old, eligible for curative-inte... |
QA:c79e9542be3e4d729f2f7282 | QAG:11126685ee85528b8336879f | provenance_qa | paper_evidence_availability | provenance_qa | G012 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:36716292? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable an... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMID:36716292","verdict":"no_released_traceable_claim","reason":"No Cla... | [] | [
"PMID:36716292"
] | [] | [] | [] | {"qa_id":"QA:c79e9542be3e4d729f2f7282","qa_group_id":"QAG:11126685ee85528b8336879f","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G012","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:36716292? E... |
QA:d32d330c109ccb161a5cf755 | QAG:2e3d04034e07496192ad1239 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "[Recommendation] The presence of the BRAF V600E mutation was associated with poor prognosis, especially in patients with microsatellite stable (MSS) resectable CRC"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance req... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:90202cc387ce05d2a16a0dd9","quotes":["[Recommendation] The presence of the BRAF V600E mutation is associated with ... | [
"CLM:90202cc387ce05d2a16a0dd9"
] | [
"PMCID:PMC7540970"
] | [
"SPAN:4f4d832acdcc95678c659167"
] | [] | [] | {"qa_id":"QA:d32d330c109ccb161a5cf755","qa_group_id":"QAG:2e3d04034e07496192ad1239","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"[Recommendation] The presence of the BRAF V600E mutation was assoc... |
QA:d35c605b48fe189b3e53b51c | QAG:7a6dc58ea52a9969de17747c | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "Bim also mediates apoptosis promoted by combined inhibition of Bcl-X L and MEK in KRAS -mutant CRC and lung cancer cells"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting pass... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:8debb7fa70fdc0e19b228aca","quotes":["Bim also mediates apoptosis induced by combined inhibition of Bcl-X L and ME... | [
"CLM:8debb7fa70fdc0e19b228aca"
] | [
"PMCID:PMC6195818"
] | [
"SPAN:5abb9721f0e646dd3a60b3b6"
] | [] | [] | {"qa_id":"QA:d35c605b48fe189b3e53b51c","qa_group_id":"QAG:7a6dc58ea52a9969de17747c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"Bim also mediates apoptosis promoted by combined inhibition of Bcl... |
QA:d7a44c0c8bd2ad4c616313aa | QAG:9c617f4cf214f627a1f1fa47 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "Epidermal growth factor receptor (EGFR) is estimated to be overexpressed in 60~80% of colorectal cancer (CRC), which was associated with a poor prognosis"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements:... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ca830ffeaaa01811786e628c","quotes":["Epidermal growth factor receptor (EGFR) is estimated to be overexpressed in ... | [
"CLM:ca830ffeaaa01811786e628c"
] | [
"PMCID:PMC7865832"
] | [
"SPAN:e5e7da88a8476b6e6d223b22"
] | [] | [] | {"qa_id":"QA:d7a44c0c8bd2ad4c616313aa","qa_group_id":"QAG:9c617f4cf214f627a1f1fa47","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"Epidermal growth factor receptor (EGFR) is estimated to be overexp... |
QA:db3543a4ab32d26c4b4f82bc | QAG:af4594de298e398528be3b43 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "A total of 26 patients with RAS-BRAF wild-type metastatic colorectal cancer receiving rechallenge with cetuximab between July 2018 and February 2021 were included in our analysis"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:6b80199e82817e05340ab2fc","quotes":["A total of 26 patients with RAS-BRAF wild-type metastatic colorectal cancer ... | [
"CLM:6b80199e82817e05340ab2fc"
] | [
"PMCID:PMC9068964"
] | [
"SPAN:450183d981ac179ee5fde512"
] | [] | [] | {"qa_id":"QA:db3543a4ab32d26c4b4f82bc","qa_group_id":"QAG:af4594de298e398528be3b43","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"A total of 26 patients with RAS-BRAF wild-type metastatic colorect... |
QA:e0681348c7344429f35b876d | QAG:3a75315b52f364135060abdd | provenance_qa | paper_evidence_availability | provenance_qa | G012 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:35723084? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable an... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMID:35723084","verdict":"no_released_traceable_claim","reason":"No Cla... | [] | [
"PMID:35723084"
] | [] | [] | [] | {"qa_id":"QA:e0681348c7344429f35b876d","qa_group_id":"QAG:3a75315b52f364135060abdd","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G012","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:35723084? E... |
QA:e0ddf774d7eba347f2045f87 | QAG:72096b38f887c553a63b9874 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "Restoring PUMA induction overcomes KRAS conferred resistance to anti-EGFR antibodies in colorectal cancer"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper,... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:d262e732ecd85e6bf7331a61","quotes":["21. Knickelbein K, Tong J, Chen D, Wang YJ, Misale ... | [
"CLM:d262e732ecd85e6bf7331a61",
"CLM:950771a6a5c45179186227f3"
] | [
"PMCID:PMC7376720",
"PMCID:PMC6195818"
] | [
"SPAN:9d52784a8a0138ae01f537a4",
"SPAN:99dd1e6e2d263653881f3ddb"
] | [
"ASC2:e73c4c1a7a3cf2382327d340"
] | [
"HYP:DCH:43c139df560c47cad994b1f0"
] | {"qa_id":"QA:e0ddf774d7eba347f2045f87","qa_group_id":"QAG:72096b38f887c553a63b9874","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"Restoring PUMA induction overcomes KRAS conferred resistance to an... |
QA:e549cbab40fcab17612f8399 | QAG:d2b34614fe40b108e7b121de | provenance_qa | paper_evidence_availability | provenance_qa | G012 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC8810873? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC8810873","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC8810873"
] | [] | [] | [] | {"qa_id":"QA:e549cbab40fcab17612f8399","qa_group_id":"QAG:d2b34614fe40b108e7b121de","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G012","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC8810873... |
QA:e793563c4a32b6e27e08ecd2 | QAG:75a66e56944acce11d7053c3 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "3% received rechallenge with anti-EGFR in fourth- or fifth-line therapy) colorectal cancer patients"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:24715b811f96f057ce6641e3","quotes":["In the present study, we explored the rechallenge strategy with cetuximab-ba... | [
"CLM:24715b811f96f057ce6641e3"
] | [
"PMCID:PMC9068964"
] | [
"SPAN:b1b6566d45cdef3af7523bcf"
] | [] | [] | {"qa_id":"QA:e793563c4a32b6e27e08ecd2","qa_group_id":"QAG:75a66e56944acce11d7053c3","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"3% received rechallenge with anti-EGFR in fourth- or fifth-line th... |
QA:eb49071f20285868ddb60392 | QAG:c453809b030aa1222b558484 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "Therefore, these results suggest that the activation of AMPK pathway may overcome the drug resistance promoted by KRAS mutation in CRC"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact s... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:f3994ff0be87b9140fd24ef9","quotes":["Therefore, these results suggest that the activation of AMPK pathway may ove... | [
"CLM:f3994ff0be87b9140fd24ef9"
] | [
"PMCID:PMC7376720"
] | [
"SPAN:943e4a310bf1b3e218f651de"
] | [] | [] | {"qa_id":"QA:eb49071f20285868ddb60392","qa_group_id":"QAG:c453809b030aa1222b558484","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"Therefore, these results suggest that the activation of AMPK pathw... |
QA:ee8890a35c37d7c61d4f2f62 | QAG:5b9674af5c71b730742b2a58 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "Results Higher levels of AMPK activity in CRC cells with wild-type KRAS treated with anti-EGFR antibody led to apoptosis induction"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact suppo... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:7322384722a7103f44da1e36","quotes":["Results Higher levels of AMPK activity in CRC cells with wild-type KRAS trea... | [
"CLM:7322384722a7103f44da1e36"
] | [
"PMCID:PMC7376720"
] | [
"SPAN:6980ea4e74efa99aed0217d2"
] | [] | [] | {"qa_id":"QA:ee8890a35c37d7c61d4f2f62","qa_group_id":"QAG:5b9674af5c71b730742b2a58","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"Results Higher levels of AMPK activity in CRC cells with wild-type... |
QA:f00df81d063738bb5bdaba37 | QAG:6ec46b8496a94ba0554dfcdc | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "e DLD1 WT (+/−) cells stably expressing control, Kras WT, or Kras mutant (G12V) by retrovirus transfection received Cet at indicated doses for 48 h"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: retur... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:48b2d45b25bfcd6afeeb91c1","quotes":["Fig. 1 Phosphorylation of ... | [
"CLM:48b2d45b25bfcd6afeeb91c1",
"CLM:6ccc3880d4186685e452727a",
"CLM:513308b69f0351967d37a6ff"
] | [
"PMCID:PMC7376720",
"PMCID:PMC6617392",
"PMCID:PMC10803265"
] | [
"SPAN:15e88f45ffc35dcf5e82a1a5",
"SPAN:aaddcb23a35f3cd789acc408",
"SPAN:e9fcda7b9b8748b3e2289d20"
] | [
"ASC2:8c0e5de569c57ccd4bb27c1a",
"ASC2:441ce188d010cb3ce6141d46"
] | [
"HYP:DCH:433099e7d4da571601da5a16"
] | {"qa_id":"QA:f00df81d063738bb5bdaba37","qa_group_id":"QAG:6ec46b8496a94ba0554dfcdc","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"e DLD1 WT (+/−) cells stably expressing control, Kras WT, or Kras ... |
QA:f1dc163440c06d7bb0956f02 | QAG:029da75fc6cfabf8d0d94df1 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "The function of AMPK in KRAS mutation promoted resistance to anti-EGFR antibodies in CRC cells, and the regulatory role of Bcl-2 family proteins in DLD1 cells with WT or mutated KRAS upon AMPK activation were investigated"? Return the original wording with paper, Claim... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:89222422fc7c3d1cbc336cc9","quotes":["The function of AMPK in KRAS mutation-induced resistance to anti-EGFR antibo... | [
"CLM:89222422fc7c3d1cbc336cc9"
] | [
"PMCID:PMC7376720"
] | [
"SPAN:4bff9f5b3bc1ee176c574256"
] | [] | [] | {"qa_id":"QA:f1dc163440c06d7bb0956f02","qa_group_id":"QAG:029da75fc6cfabf8d0d94df1","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"The function of AMPK in KRAS mutation promoted resistance to anti-... |
QA:f6cb41aef833f14a0770685c | QAG:bbda1ddf544d76284cdc0f1d | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "Monoclonal antibodies targeting epidermal growth factor receptors (EGFRs) have led to significant improvements in survival for patients with metastatic colorectal cancer (mCRC)"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated p... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:7fc1c76d4959c7b871353daf","quotes":["Monoclonal antibodies targeting epidermal growth factor receptors (EGFRs) ha... | [
"CLM:7fc1c76d4959c7b871353daf"
] | [
"PMCID:PMC10712701"
] | [
"SPAN:a94870ad421ea3d3f396139b"
] | [] | [] | {"qa_id":"QA:f6cb41aef833f14a0770685c","qa_group_id":"QAG:bbda1ddf544d76284cdc0f1d","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"Monoclonal antibodies targeting epidermal growth factor receptors ... |
QA:fb35e0222086f4264f1ebfaa | QAG:43f8502d88a9c3258158c79e | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "33 Our pilot study clearly showed a clinical benefit of anti-EGFR treatment added to cytotoxics for those patients with metastatic RAS -mt CRC who display RAS -wt ctDNA and have received cetuximab-based chemotherapy as second-line to fourth-line therapy"? Return the or... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:e411b1b75ece3ac911617438","quotes":["33 Our pilot study clearly showed a clinical benefi... | [
"CLM:e411b1b75ece3ac911617438",
"CLM:d9898dfcc151b288bf13cd9a"
] | [
"PMCID:PMC7529530",
"PMCID:PMC9068964"
] | [
"SPAN:1eb3dacd649a5a4c446d0110",
"SPAN:eaf521be704ef354dea33052"
] | [
"ASC2:2bd397b73c46f8805a5e83dd"
] | [
"HYP:DCH:9fe9e39cfaabda723624f4da"
] | {"qa_id":"QA:fb35e0222086f4264f1ebfaa","qa_group_id":"QAG:43f8502d88a9c3258158c79e","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"33 Our pilot study clearly showed a clinical benefit of anti-EGFR ... |
QA:fe38834ab5892dfde467ba33 | QAG:c20737b795841b469bda81c2 | provenance_qa | exact_evidence_retrieval | provenance_qa | G012 | en | train | Which exact source passage supports the statement "We assessed the applicability of this approach in a cohort of patients with metastatic colorectal cancer (mCRC), with both RAS/BRAF wildtype and left-sided primary tumors, who received doublet chemotherapy and were eligible for anti-EGFR mAb therapy ( 17–20 )"? Return ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:920ec9b76ebf1e08b6f2d83f","quotes":["We assessed the applicability of this approach in a cohort of patients with ... | [
"CLM:920ec9b76ebf1e08b6f2d83f"
] | [
"PMCID:PMC9975664"
] | [
"SPAN:cc542c033c7d8a953fb0d3d9"
] | [] | [] | {"qa_id":"QA:fe38834ab5892dfde467ba33","qa_group_id":"QAG:c20737b795841b469bda81c2","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G012","question":"Which exact source passage supports the statement \"We assessed the applicability of this approach in a cohort of pati... |
QA:006808de2eafb976649f66cf | QAG:09e7f2f07c51b6f2a4228a62 | provenance_qa | exact_evidence_retrieval | provenance_qa | G013 | en | train | Which exact source passage supports the statement "24 demonstrated that MGP promoted colon cancer cell proliferation by activating the NF-κB pathway through upregulation of the calcium signaling pathway, and the potential correlation between MGP and the tumor microenvironment was improved by using PD-L1 as an intermedi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:5f3de0969066f18485561a7f","quotes":["Li et al. 24 demonstrated that MGP promoted colon c... | [
"CLM:5f3de0969066f18485561a7f",
"CLM:0478df56bd5aa1173e674769",
"CLM:06ac56904fbab2322b5096d2"
] | [
"PMCID:PMC8990480",
"PMCID:PMC6700499"
] | [
"SPAN:655f9290a733cb8520c27068",
"SPAN:c0c5cb5b1045c15be72b7400"
] | [
"ASC2:2b9f20ef817c11994396db29"
] | [
"HYP:DCH:1642de8faac50c1df15286c8"
] | {"qa_id":"QA:006808de2eafb976649f66cf","qa_group_id":"QAG:09e7f2f07c51b6f2a4228a62","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G013","question":"Which exact source passage supports the statement \"24 demonstrated that MGP promoted colon cancer cell proliferation ... |
QA:009c29b39f54ff6774213f5e | QAG:e2a1589460283983165ddeea | provenance_qa | exact_evidence_retrieval | provenance_qa | G013 | en | train | Which exact source passage supports the statement "in addition, the tumor colony growth in the livers of nude mice was decreased by the administration of CM from THP-1 cells promoted with PMA (Fig. 6 c–g and Additional file 8 : Fig. S8)"? Return the original wording with paper, Claim, and Evidence Span references.
Int... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:067d965206482629e87c81c8","quotes":["In vitro and in vivo assays demonstrated that the n... | [
"CLM:067d965206482629e87c81c8",
"CLM:0478df56bd5aa1173e674769",
"CLM:08da93eb5093324759b21e14"
] | [
"PMCID:PMC7678301",
"PMCID:PMC6751205"
] | [
"SPAN:b8226aa0425918e91db8b76a",
"SPAN:7a8eac19041000316563bf1a"
] | [
"ASC2:f2e9a6f1bd5884c73674a21d"
] | [] | {"qa_id":"QA:009c29b39f54ff6774213f5e","qa_group_id":"QAG:e2a1589460283983165ddeea","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G013","question":"Which exact source passage supports the statement \"in addition, the tumor colony growth in the livers of nude mice wa... |
QA:064afe69c154cd06f86e2dcc | QAG:ad43538c1d3c9fd9beb6ad52 | provenance_qa | exact_evidence_retrieval | provenance_qa | G013 | en | train | Which exact source passage supports the statement "More than two third of our patients with distance metastasis had increased concentrations, by contrast, 100% of the 11 recurrence patients with liver metastasis had abnormal MIC-1 serum concentrations, suggesting that CRC patients with liver metastasis may produce more... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ce6443e638fb2cdc269b7919","quotes":["More than two third of our patients with distance metastasis had elevated co... | [
"CLM:ce6443e638fb2cdc269b7919",
"CLM:71ac756b9724a4423f9240ec"
] | [
"PMCID:PMC5421897"
] | [
"SPAN:6c807116b056ba78c85df20f"
] | [] | [] | {"qa_id":"QA:064afe69c154cd06f86e2dcc","qa_group_id":"QAG:ad43538c1d3c9fd9beb6ad52","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G013","question":"Which exact source passage supports the statement \"More than two third of our patients with distance metastasis had i... |
QA:06b5af23ff832e922283ef40 | QAG:071b98f96d97ed77402cef58 | provenance_qa | exact_evidence_retrieval | provenance_qa | G013 | en | train | Which exact source passage supports the statement "Consistent with the data from mice samples, the expression of CCL2 and CCR2 was higher than the human hepatic metastases than primary CRC samples validated by immunohistochemistry and Q-PCR (Fig. 5 F, G)"? Return the original wording with paper, Claim, and Evidence Spa... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:a9d36856ad3f2c53f2d3c74a","quotes":["Consistent with the data from mice samples, the exp... | [
"CLM:a9d36856ad3f2c53f2d3c74a",
"CLM:0478df56bd5aa1173e674769",
"CLM:4dcb3ff8cb620a67e31ef832"
] | [
"PMCID:PMC8476489",
"PMCID:PMC6140580"
] | [
"SPAN:03b20bf83a82009f2fac13b2",
"SPAN:800236dc949ad276b52e37ca"
] | [
"ASC2:34ab6f454250145c4051ab0d"
] | [
"HYP:DCH:70ef1a0dc11a69c57a52925d"
] | {"qa_id":"QA:06b5af23ff832e922283ef40","qa_group_id":"QAG:071b98f96d97ed77402cef58","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G013","question":"Which exact source passage supports the statement \"Consistent with the data from mice samples, the expression of CCL2... |
QA:07228b389e72c54b07693f0a | QAG:52675f06b1d7f631847f47ff | provenance_qa | exact_evidence_retrieval | provenance_qa | G013 | en | train | Which exact source passage supports the statement "24 reported that MGP promoted the growth and proliferation of colon cancer cells"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and Evidence Span... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:4422372163477ffeb8e179d3","quotes":["For instance, Li et al. 24 reported that MGP promoted the growth and prolife... | [
"CLM:4422372163477ffeb8e179d3",
"CLM:0478df56bd5aa1173e674769"
] | [
"PMCID:PMC8990480"
] | [
"SPAN:1638e6601a214db8eade2d56"
] | [] | [] | {"qa_id":"QA:07228b389e72c54b07693f0a","qa_group_id":"QAG:52675f06b1d7f631847f47ff","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G013","question":"Which exact source passage supports the statement \"24 reported that MGP promoted the growth and proliferation of colo... |
QA:07d9e9774fbb07ad04453b36 | QAG:dd9dd888d13504d59183feea | provenance_qa | paper_evidence_availability | provenance_qa | G013 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC3561803? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC3561803","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC3561803"
] | [] | [] | [] | {"qa_id":"QA:07d9e9774fbb07ad04453b36","qa_group_id":"QAG:dd9dd888d13504d59183feea","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G013","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC3561803... |
QA:082a2c4010e698dd24c4f6db | QAG:d72df3cd59c06a475f52bc0c | provenance_qa | exact_evidence_retrieval | provenance_qa | G013 | en | train | Which exact source passage supports the statement "Spearman correlation analysis showed that the CD163 positivity rate was associated with miR-934 expression in 50 CRC tissues"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:562ffc36d0aef546e037fa1d","quotes":["Spearman correlation analysis showed that the CD163 positivity rate was posi... | [
"CLM:562ffc36d0aef546e037fa1d",
"CLM:0478df56bd5aa1173e674769"
] | [
"PMCID:PMC7678301"
] | [
"SPAN:3de91d0f23c7a78a707ec53a"
] | [] | [] | {"qa_id":"QA:082a2c4010e698dd24c4f6db","qa_group_id":"QAG:d72df3cd59c06a475f52bc0c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G013","question":"Which exact source passage supports the statement \"Spearman correlation analysis showed that the CD163 positivity rat... |
QA:0836a78e2da13516e5ef1f14 | QAG:3fe35aef0caf2f61b7bf8669 | provenance_qa | exact_evidence_retrieval | provenance_qa | G013 | en | train | Which exact source passage supports the statement "vaccination strategies or anti-IL-6 or anti-IL-21 antibodies) increased the anti-tumorigenic response"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Cla... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:59829d00fd21daf6f667da9c","quotes":["In pre-clinical research using subcutaneous (s.c.) colon cancer models, dual... | [
"CLM:59829d00fd21daf6f667da9c",
"CLM:0478df56bd5aa1173e674769"
] | [
"PMCID:PMC6700499"
] | [
"SPAN:c55fe3500943601126046b56"
] | [] | [] | {"qa_id":"QA:0836a78e2da13516e5ef1f14","qa_group_id":"QAG:3fe35aef0caf2f61b7bf8669","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G013","question":"Which exact source passage supports the statement \"vaccination strategies or anti-IL-6 or anti-IL-21 antibodies) incr... |
QA:0872b58807c239473341d0cd | QAG:f37d9708f6604898afc17eae | provenance_qa | exact_evidence_retrieval | provenance_qa | G013 | en | train | Which exact source passage supports the statement "(G) After spleen injection of MC38-Luc cells to construct a colorectal cancer liver metastasis model, the liver metastasis model mice received OI (i.p.) (50 mg/kg/2 day) or PBS for 3 weeks"? Return the original wording with paper, Claim, and Evidence Span references.
... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:a6929363b9ba3172f5040728","quotes":["(G) After spleen injection of MC38-Luc cells to con... | [
"CLM:a6929363b9ba3172f5040728",
"CLM:7795cac80522afb92a0dc44d",
"CLM:e42f1b9914c359e2967c6230"
] | [
"PMCID:PMC10405073",
"PMCID:PMC8908934"
] | [
"SPAN:fc2efcbbd83421e14357a4d2",
"SPAN:169f8ea2d1aae3140d2dace9"
] | [
"ASC2:fe464743a38297de83f1c4e4"
] | [
"HYP:DCH:d41f53abe04971cdda79cee0"
] | {"qa_id":"QA:0872b58807c239473341d0cd","qa_group_id":"QAG:f37d9708f6604898afc17eae","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G013","question":"Which exact source passage supports the statement \"(G) After spleen injection of MC38-Luc cells to construct a colore... |
QA:09b19edccf4aae531dfdece6 | QAG:0c27e89f21986ce3fb2b2d26 | provenance_qa | paper_evidence_availability | provenance_qa | G013 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC9525122? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC9525122","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC9525122"
] | [] | [] | [] | {"qa_id":"QA:09b19edccf4aae531dfdece6","qa_group_id":"QAG:0c27e89f21986ce3fb2b2d26","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G013","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC9525122... |
QA:09eef805ffab836cec0a5d21 | QAG:55aae9cf148d90b9e08a3dc2 | provenance_qa | exact_evidence_retrieval | provenance_qa | G013 | en | train | Which exact source passage supports the statement "d A transwell assay showed S1PR1 overexpression promoted cell migration and invasion of SW480 and S1PR1 knockdown significantly inhibited the migration and invasion of HCT116. e The morphological characteristics of subcutaneous tumors with S1PR1 overexpression in SW480... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:28a29154245bd39878eb8759","quotes":["Fig. 2 S1PR1 promote CRC cell proliferation, invasion, migration and liver m... | [
"CLM:28a29154245bd39878eb8759",
"CLM:71ac756b9724a4423f9240ec"
] | [
"PMCID:PMC6751205"
] | [
"SPAN:7a8eac19041000316563bf1a"
] | [] | [] | {"qa_id":"QA:09eef805ffab836cec0a5d21","qa_group_id":"QAG:55aae9cf148d90b9e08a3dc2","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G013","question":"Which exact source passage supports the statement \"d A transwell assay showed S1PR1 overexpression promoted cell migr... |
QA:0a77ad7d4686692859f5b484 | QAG:73a5d3b4813f57eaf575857b | provenance_qa | exact_evidence_retrieval | provenance_qa | G013 | en | train | Which exact source passage supports the statement "Colorectal cancer (CRC) is the third most common cancer worldwide, and has increased in prevalence in recent years"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage wi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:4580da9d7283ea57c52a3931","quotes":["Colorectal cancer (CRC) is the third most common cancer worldwide, and has i... | [
"CLM:4580da9d7283ea57c52a3931",
"CLM:0478df56bd5aa1173e674769"
] | [
"PMCID:PMC6754330"
] | [
"SPAN:61fae162b97b68a5d52693ab"
] | [] | [] | {"qa_id":"QA:0a77ad7d4686692859f5b484","qa_group_id":"QAG:73a5d3b4813f57eaf575857b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G013","question":"Which exact source passage supports the statement \"Colorectal cancer (CRC) is the third most common cancer worldwide,... |
QA:0a8810285a08e739e1e39799 | QAG:649e4af14b16f8239c8110c1 | provenance_qa | exact_evidence_retrieval | provenance_qa | G013 | en | train | Which exact source passage supports the statement "According to the in vivo results, the downregulated expression of MGP inhibited liver metastasis of CRC, compared with the sh-NC group"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact s... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:bfb8637b5cf99d872b9a98c8","quotes":["According to the in vivo results, the downregulated expression of MGP signif... | [
"CLM:bfb8637b5cf99d872b9a98c8",
"CLM:71ac756b9724a4423f9240ec"
] | [
"PMCID:PMC8990480"
] | [
"SPAN:80b6807e7b2aff1c63b0df1b"
] | [] | [] | {"qa_id":"QA:0a8810285a08e739e1e39799","qa_group_id":"QAG:649e4af14b16f8239c8110c1","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G013","question":"Which exact source passage supports the statement \"According to the in vivo results, the downregulated expression of ... |
QA:0b059ea36a98c3cc64b5835d | QAG:ada231447fd2a063ffa39f77 | provenance_qa | exact_evidence_retrieval | provenance_qa | G013 | en | train | Which exact source passage supports the statement "17 To confirm whether the liver damage was associated with liver metastasis or tumour alone, we compared the liver injury in mice bearing subcutaneous tumour or mice which have liver metastasis of colon cancer cells"? Return the original wording with paper, Claim, and ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:317c6f278caa454b2d65c295","quotes":["17 To confirm whether the liver damage is associated with liver metastasis o... | [
"CLM:317c6f278caa454b2d65c295",
"CLM:7795cac80522afb92a0dc44d"
] | [
"PMCID:PMC6378193"
] | [
"SPAN:6ce8f441b96654fd465deae0"
] | [] | [] | {"qa_id":"QA:0b059ea36a98c3cc64b5835d","qa_group_id":"QAG:ada231447fd2a063ffa39f77","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G013","question":"Which exact source passage supports the statement \"17 To confirm whether the liver damage was associated with liver m... |
QA:0d175e62923ef89cc9e8e774 | QAG:b1ccf55967c37e9fcc51e125 | provenance_qa | exact_evidence_retrieval | provenance_qa | G013 | en | train | Which exact source passage supports the statement "Our results showed that subcutaneous tumour xenograft without liver metastasis resulted in liver injury, but liver metastasis of colon cancer cells caused much more serious liver injury, which was associated with more recruitment of F4/80 + macrophages but not CD3 + T ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:df164f2a7c962e2fdc2ddd9e","quotes":["Our results showed that subcutaneous tumour xenogra... | [
"CLM:df164f2a7c962e2fdc2ddd9e",
"CLM:71ac756b9724a4423f9240ec",
"CLM:3450f2f545328d62ada5aeda"
] | [
"PMCID:PMC6378193",
"PMCID:PMC5041936"
] | [
"SPAN:2ca3e8163c1c30663fa0fbef",
"SPAN:0c4faf1ee58cbe9ba7318f09"
] | [
"ASC2:48f64d4fd222cbc2583a321f"
] | [
"HYP:DCH:e054fecce5df0359b8a4787a"
] | {"qa_id":"QA:0d175e62923ef89cc9e8e774","qa_group_id":"QAG:b1ccf55967c37e9fcc51e125","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G013","question":"Which exact source passage supports the statement \"Our results showed that subcutaneous tumour xenograft without live... |
QA:0d28698f4f1c2ac21e0b3084 | QAG:2f323378d5d574f81b98545c | provenance_qa | exact_evidence_retrieval | provenance_qa | G013 | en | train | Which exact source passage supports the statement "c A wound healing assay showed S1PR1 overexpression significantly promoted cell migration of SW480 and S1PR1 knockdown inhibited the migration of HCT116, 36 h after wounding. d A transwell assay showed S1PR1 overexpression significantly promoted cell migration and inva... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:a0c795f4cffbacc0ffbfcdff","quotes":["Fig. 2 S1PR1 promote CRC cell proliferation, invasion, migration and liver m... | [
"CLM:a0c795f4cffbacc0ffbfcdff",
"CLM:71ac756b9724a4423f9240ec"
] | [
"PMCID:PMC6751205"
] | [
"SPAN:7a8eac19041000316563bf1a"
] | [] | [] | {"qa_id":"QA:0d28698f4f1c2ac21e0b3084","qa_group_id":"QAG:2f323378d5d574f81b98545c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G013","question":"Which exact source passage supports the statement \"c A wound healing assay showed S1PR1 overexpression significantly ... |
QA:0fe7fadde9eb2b5345e674b2 | QAG:9461a3005fec631d3c1aef2a | provenance_qa | exact_evidence_retrieval | provenance_qa | G013 | en | train | Which exact source passage supports the statement "25 Huang et al showed IL-9 has low amounts in tissue and plasma specimens from individuals with colon carcinoma, and these low levels was associated with tumor progression"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated proven... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:e59cb24b861761e6ffc89ce1","quotes":["25 Huang et al showed IL-9 has low amounts in tissue and plasma specimens fr... | [
"CLM:e59cb24b861761e6ffc89ce1",
"CLM:0478df56bd5aa1173e674769"
] | [
"PMCID:PMC6598323"
] | [
"SPAN:1416df1e6eb29ef52488c0ca"
] | [] | [] | {"qa_id":"QA:0fe7fadde9eb2b5345e674b2","qa_group_id":"QAG:9461a3005fec631d3c1aef2a","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G013","question":"Which exact source passage supports the statement \"25 Huang et al showed IL-9 has low amounts in tissue and plasma sp... |
QA:1036eeaa0e8b2c217a9dca68 | QAG:e3424c1c0909a2c851504ddb | provenance_qa | exact_evidence_retrieval | provenance_qa | G013 | en | train | Which exact source passage supports the statement "d A transwell assay showed S1PR1 overexpression significantly promoted cell migration and invasion of SW480 and S1PR1 knockdown inhibited the migration and invasion of HCT116. e The morphological characteristics of subcutaneous tumors with S1PR1 overexpression in SW480... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:08da93eb5093324759b21e14","quotes":["Fig. 2 S1PR1 promote CRC cell proliferation, invasi... | [
"CLM:08da93eb5093324759b21e14",
"CLM:71ac756b9724a4423f9240ec",
"CLM:4d26b093e9d96cfd8c6b6e3d"
] | [
"PMCID:PMC6751205",
"PMCID:PMC8671452"
] | [
"SPAN:7a8eac19041000316563bf1a",
"SPAN:5f385971b91e3a5b1562883c"
] | [
"ASC2:485c6e6a1949393d00a405e0"
] | [
"HYP:DCH:d3b30cb2630c67247def787f"
] | {"qa_id":"QA:1036eeaa0e8b2c217a9dca68","qa_group_id":"QAG:e3424c1c0909a2c851504ddb","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G013","question":"Which exact source passage supports the statement \"d A transwell assay showed S1PR1 overexpression significantly prom... |
QA:10b145069706b0923cb75438 | QAG:317a326dd157bb27fddc1bd4 | provenance_qa | exact_evidence_retrieval | provenance_qa | G013 | en | train | Which exact source passage supports the statement "In vitro and in vivo assays demonstrated that the numbers of migratory and invasive SW480 and RKO cells in groups administered CM from THP-1 cells stimulated with PMA, which received exosomes derived from miR-934-overexpressing or miR-934-downregulated CRC cells, were ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:d4dc0c196342e82f8f1178cf","quotes":["In vitro and in vivo assays demonstrated that the numbers of migratory and i... | [
"CLM:d4dc0c196342e82f8f1178cf",
"CLM:0478df56bd5aa1173e674769"
] | [
"PMCID:PMC7678301"
] | [
"SPAN:b8226aa0425918e91db8b76a"
] | [] | [] | {"qa_id":"QA:10b145069706b0923cb75438","qa_group_id":"QAG:317a326dd157bb27fddc1bd4","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G013","question":"Which exact source passage supports the statement \"In vitro and in vivo assays demonstrated that the numbers of migra... |
QA:11bc9ad1c3797d4ea1e77824 | QAG:86bf4a7234567a8b29271a4d | provenance_qa | exact_evidence_retrieval | provenance_qa | G013 | en | train | Which exact source passage supports the statement "in addition, the tumor colony growth in the livers of nude mice was decreased by the administration of CM from THP-1 cells stimulated with PMA (Fig. 6 c–g and Additional file 8 : Fig. S8)"? Return the original wording with paper, Claim, and Evidence Span references.
I... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:fec67e253880bffb6165c17e","quotes":["In vitro and in vivo assays demonstrated that the numbers of migratory and i... | [
"CLM:fec67e253880bffb6165c17e",
"CLM:0478df56bd5aa1173e674769"
] | [
"PMCID:PMC7678301"
] | [
"SPAN:b8226aa0425918e91db8b76a"
] | [] | [] | {"qa_id":"QA:11bc9ad1c3797d4ea1e77824","qa_group_id":"QAG:86bf4a7234567a8b29271a4d","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G013","question":"Which exact source passage supports the statement \"in addition, the tumor colony growth in the livers of nude mice wa... |
QA:121fa7bcd0f263021ec50543 | QAG:356920245bffc18f5bfe784a | provenance_qa | exact_evidence_retrieval | provenance_qa | G013 | en | train | Which exact source passage supports the statement "Compared to previous studies, we included qRT-PCR to quantitatively determine IL-9 mRNA levels in human colon carcinoma and adjacent noncancerous tissue specimens and found that IL-9 expression in colon carcinoma was correlated with patient survival"? Return the origin... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:5722bac2efe23df584344062","quotes":["Compared to previous studies, we included qRT-PCR to quantitatively determin... | [
"CLM:5722bac2efe23df584344062",
"CLM:3c9947cdb5135d5ca5bd3ac4"
] | [
"PMCID:PMC6598323"
] | [
"SPAN:e30c8d67b11c106e8f02b71b"
] | [] | [] | {"qa_id":"QA:121fa7bcd0f263021ec50543","qa_group_id":"QAG:356920245bffc18f5bfe784a","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G013","question":"Which exact source passage supports the statement \"Compared to previous studies, we included qRT-PCR to quantitativel... |
QA:127618b251b41a4ca40d0d60 | QAG:d7861fc3620041153974dd62 | provenance_qa | exact_evidence_retrieval | provenance_qa | G013 | en | train | Which exact source passage supports the statement "Figure 5 Fusobacterium nucleatum– promoted intestinal microbial dysbiosis is involved in the development of colorectal cancer liver metastasis. ( A – D ) The rarefaction curve ( A ), relative abundance curve ( B ), Shannon diversity index ( C ), and Chao1 diversity ind... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:e42f1b9914c359e2967c6230","quotes":["Figure 5 Fusobacterium nucleatum– induced intestina... | [
"CLM:e42f1b9914c359e2967c6230",
"CLM:7795cac80522afb92a0dc44d",
"CLM:15e244a548ca920383903c3d",
"CLM:a6929363b9ba3172f5040728"
] | [
"PMCID:PMC8908934",
"PMCID:PMC7678301",
"PMCID:PMC10405073"
] | [
"SPAN:169f8ea2d1aae3140d2dace9",
"SPAN:b6b151f26760ee21dcaa7568",
"SPAN:fc2efcbbd83421e14357a4d2"
] | [
"ASC2:b8c2cc6526e36e8e436e6c24",
"ASC2:fe464743a38297de83f1c4e4"
] | [
"HYP:DCH:cf19078b38ba9988d0f92e26"
] | {"qa_id":"QA:127618b251b41a4ca40d0d60","qa_group_id":"QAG:d7861fc3620041153974dd62","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G013","question":"Which exact source passage supports the statement \"Figure 5 Fusobacterium nucleatum– promoted intestinal microbial dy... |
QA:12b646b47696d0d1136c9a4c | QAG:7dfafaa19d541d6ff1c5fe36 | provenance_qa | exact_evidence_retrieval | provenance_qa | G013 | en | train | Which exact source passage supports the statement "Our study showed that targeting the CCL2/CCR2 chemokine axis decreases TAM at the metastatic site, disrupting the immunosuppressive TME and rendering mCRC susceptible to anti-tumor T-cell responses"? Return the original wording with paper, Claim, and Evidence Span refe... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:4f4a46d05061b46ef94def48","quotes":["Our study suggests that targeting the CCL2/CCR2 chemokine axis decreases TAM... | [
"CLM:4f4a46d05061b46ef94def48",
"CLM:04bbc50258758972aa54295d"
] | [
"PMCID:PMC6140580"
] | [
"SPAN:ec9ade3dbb77a92bf42ee19c"
] | [] | [] | {"qa_id":"QA:12b646b47696d0d1136c9a4c","qa_group_id":"QAG:7dfafaa19d541d6ff1c5fe36","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G013","question":"Which exact source passage supports the statement \"Our study showed that targeting the CCL2/CCR2 chemokine axis decre... |
QA:13f4e463b9a6ca2ca10a7759 | QAG:092ec28a4b18363e3de1034a | provenance_qa | exact_evidence_retrieval | provenance_qa | G013 | en | train | Which exact source passage supports the statement "Further analysis indicated that TCF4 expression in the cancer cells was correlated with the TAMs infiltration and M2 polarization in the CRC tumor tissue"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements:... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:3a770a69432323915ad997cc","quotes":["Further analysis indicated that TCF4 expression in the cancer cells is corre... | [
"CLM:3a770a69432323915ad997cc",
"CLM:0478df56bd5aa1173e674769"
] | [
"PMCID:PMC8476489"
] | [
"SPAN:6c69eb41910f01fec4587cae"
] | [] | [] | {"qa_id":"QA:13f4e463b9a6ca2ca10a7759","qa_group_id":"QAG:092ec28a4b18363e3de1034a","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G013","question":"Which exact source passage supports the statement \"Further analysis indicated that TCF4 expression in the cancer cell... |
QA:167b7ac0af04a060be2c090a | QAG:237349d511fa086ef952f074 | provenance_qa | exact_evidence_retrieval | provenance_qa | G013 | en | train | Which exact source passage supports the statement "473 patients with CRC diagnosed between 2009 and 2011 from cancer institute and hospital, Chinese Academy of Medical Sciences (CICAMS), 25 patients with benign adenomatous polyp diagnosed by pathological examination and 489 healthy age- and gender-matched subjects were... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:6d79e2b87738d61b595e9962","quotes":["473 patients with CRC diagnosed between 2009 and 2011 from cancer institute ... | [
"CLM:6d79e2b87738d61b595e9962",
"CLM:0478df56bd5aa1173e674769"
] | [
"PMCID:PMC5421897"
] | [
"SPAN:ca33745897a79393d6b8ef0f"
] | [] | [] | {"qa_id":"QA:167b7ac0af04a060be2c090a","qa_group_id":"QAG:237349d511fa086ef952f074","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G013","question":"Which exact source passage supports the statement \"473 patients with CRC diagnosed between 2009 and 2011 from cancer ... |
QA:17b2977613a54d03c4dc605a | QAG:545c7f13dd400e2894663695 | provenance_qa | exact_evidence_retrieval | provenance_qa | G013 | en | train | Which exact source passage supports the statement "1 Changes in gut microbiota and colorectal cancer (CRC) liver metastasis promoted by different antibiotics"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:660580ccdf65ab6b89af65fb","quotes":["20 Fig. 1 Changes in gut microbiota and colorectal cancer (CRC) liver metast... | [
"CLM:660580ccdf65ab6b89af65fb",
"CLM:71ac756b9724a4423f9240ec"
] | [
"PMCID:PMC9289841"
] | [
"SPAN:2097b1dd115ef2f6eef45a8d"
] | [] | [] | {"qa_id":"QA:17b2977613a54d03c4dc605a","qa_group_id":"QAG:545c7f13dd400e2894663695","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G013","question":"Which exact source passage supports the statement \"1 Changes in gut microbiota and colorectal cancer (CRC) liver meta... |
QA:184ad9c2de2e6134aa4c5096 | QAG:5a6271e189ac066ea1dc8010 | provenance_qa | exact_evidence_retrieval | provenance_qa | G013 | en | train | Which exact source passage supports the statement "In pancreatic cancer, it has been found that IL17 promoted neutrophil extracellular traps could mediate resistance to ICIs 11 , and neutrophils in tumors effectively suppress normal T-cell immunity in gastric cancer 35"? Return the original wording with paper, Claim, a... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:f9d1db89383e1fcf495831ef","quotes":["In pancreatic cancer, it has been found that IL17-induced neutrophil extrace... | [
"CLM:f9d1db89383e1fcf495831ef",
"CLM:0012c5301a22fe572fa575f9"
] | [
"PMCID:PMC9705377"
] | [
"SPAN:48b4dfe00f8b1e83a8dc0f1e"
] | [] | [] | {"qa_id":"QA:184ad9c2de2e6134aa4c5096","qa_group_id":"QAG:5a6271e189ac066ea1dc8010","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G013","question":"Which exact source passage supports the statement \"In pancreatic cancer, it has been found that IL17 promoted neutrop... |
QA:1b13abf0a478121f312cc7e6 | QAG:57d4919037b46bbb32188fd1 | provenance_qa | exact_evidence_retrieval | provenance_qa | G013 | en | train | Which exact source passage supports the statement "C The receiving primary tumor resection CRC mice received CCL7 inhibitor Bindarit or MDSC inhibitor Entinostat, and their metastases were observed by Bruber In Vivo MS FX Pro Imager"? Return the original wording with paper, Claim, and Evidence Span references.
Integra... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:3d01862b9b6a0ecf76f03a71","quotes":["C The receiving primary tumor resection CRC mice were treated with CCL7 inhi... | [
"CLM:3d01862b9b6a0ecf76f03a71",
"CLM:0478df56bd5aa1173e674769"
] | [
"PMCID:PMC8119947"
] | [
"SPAN:62768bec20738a16e71d5e50"
] | [] | [] | {"qa_id":"QA:1b13abf0a478121f312cc7e6","qa_group_id":"QAG:57d4919037b46bbb32188fd1","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G013","question":"Which exact source passage supports the statement \"C The receiving primary tumor resection CRC mice received CCL7 inh... |
QA:1caad6ff7e368965fd7541ee | QAG:6312802fcf5b75e61abf5f32 | provenance_qa | exact_evidence_retrieval | provenance_qa | G013 | en | train | Which exact source passage supports the statement "Our results showed that subcutaneous tumour xenograft without liver metastasis led to liver injury, but liver metastasis of colon cancer cells caused much more serious liver injury, which was associated with more recruitment of F4/80 + macrophages but not CD3 + T cells... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:eef2cb82a55ca7713650bed9","quotes":["Our results showed that subcutaneous tumour xenograft without liver metastas... | [
"CLM:eef2cb82a55ca7713650bed9",
"CLM:71ac756b9724a4423f9240ec"
] | [
"PMCID:PMC6378193"
] | [
"SPAN:2ca3e8163c1c30663fa0fbef"
] | [] | [] | {"qa_id":"QA:1caad6ff7e368965fd7541ee","qa_group_id":"QAG:6312802fcf5b75e61abf5f32","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G013","question":"Which exact source passage supports the statement \"Our results showed that subcutaneous tumour xenograft without live... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.